BSGI Shown to Reveal Additional Tumors in Breast Cancer Patients

A total of 82 patients underwent BSGI for newly diagnosed breast cancer; of these, 18 had an additional abnormality, and 17 were biopsied.

The study's findings were presented at the American Society of Breast Surgeons 2009 annual meeting in San Diego, CA, USA, in April 2009.

BSGI, a molecular breast imaging technique, is an adjunct to mammography that can visualize lesions independent of tissue density and discover early stage tumors. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and typically appear as "dark spots” on the BSGI image.

"We wanted to determine the number of patients with known breast cancer who were found to have an additional lesion detected by BSGI, but undetected by mammography,” said Dr. Susan K. Boolbol, chief of breast surgery at Beth Israel Medical Center (New York, NY, USA). "In our study group, 22% of patients had a change in surgical management based on BSGI findings. This is critical information in our desire to diagnose breast cancer early for successful treatment.”

BSGI provides the capability of helping differentiate cancer from other structures or benign tissue in the breast. Unlike mammography, BSGI is not affected by tissue density. The test is especially useful for patients who have dense breasts, scar tissue, implants, or palpable lesions that cannot be detected using mammography or ultrasound.

Dr. Boolbol and her team conducted an Institutional Review Board- (IRB)-approved review of all patients who underwent BSGI at Beth Israel Medical Center from 2005 to 2008. A total of 82 patients underwent BSGI for newly diagnosed breast cancer. There were five cases of invasive ductal carcinoma, two ductal carcinoma in situ (DCIS), one lobular carcinoma in situ (LCIS), two papillomas, and eight benign biopsies. One patient proceeded directly to mastectomy and an area of DCIS was found, which corresponded to the BSGI.

In conclusion, in the study group, 22% of patients had a change in surgical management based on BSGI findings. BSGI detected additional cancer in 9% of patients. "We know that mammography will not detect all breast cancers. This study proves that BSGI is an additional tool to detect breast cancers otherwise missed by standard imaging. Therefore, BSGI plays an important role in the clinical management of patients with known breast cancer,” said Dr. Boolbol.

On such system used for the BSGI technique is the Dilon Technologies, Inc.'s (Newport News, VA, USA) 6800 gamma camera is a high-resolution, compact gamma camera. The system is optimized to perform BSGI, which is a molecular breast imaging procedure that images the metabolic activity of breast lesions through radiotracer uptake.

Related Links:
Beth Israel Medical Center
Dilon Technologies